The Canadian Genetic Diseases Network (CGDN) is Canada's premier collaborative research network dedicated to advancing our nation's scientific and commercial competitiveness in genetic research. As a Network of Centres of Excellence, we bring together leading researchers, core facilities, hospitals, universities and industry partners from across the country to accelerate the application of genetic discoveries to the prevention, diagnosis and treatment of human disease.
Since our establishment in 1998, CGDN has served as the primary catalyst for translating fundamental genetic research into tangible clinical and commercial outcomes that improve the lives of Canadians and people worldwide.
CGDN exists to be the primary catalyst in advancing Canada's scientific and commercial competitiveness in genetic research and the application of genetic discoveries to the prevention, diagnosis and treatment of human disease. We pursue this mission through strategic investment in collaborative research programs, provision of world-class core facilities and technologies, comprehensive training of the next generation of genetics researchers, and active facilitation of commercialization pathways that bring discoveries from the laboratory to the patient.
As a Network of Centres of Excellence, CGDN operates at the intersection of academia, clinical medicine and industry. We connect more than 100 principal investigators and hundreds of trainees working at universities, teaching hospitals and research institutes across Canada. This collaborative structure enables us to tackle complex genetic questions that no single institution could address alone.
Our network model fosters knowledge exchange, resource sharing and interdisciplinary collaboration. Researchers in Vancouver work seamlessly with colleagues in Montreal, Toronto, Edmonton and Halifax, supported by our coordinated infrastructure and management. Industry partners gain access to cutting-edge research capabilities and emerging talent, while academic researchers benefit from commercial expertise and pathways to real-world application.
This unique structure has proven remarkably productive. Our investigators have published more than 770 scientific papers and filed over 100 patent applications, demonstrating both scientific excellence and commitment to translating discoveries into practical innovations.
CGDN serves as the connective tissue linking three essential components of Canada's genetic research ecosystem: investigators, core facilities and highly qualified personnel.
Our research programs bring together multidisciplinary teams focused on understanding the genetic basis of human disease. From identifying disease genes to characterizing their function and developing therapeutic interventions, CGDN investigators work collaboratively across traditional boundaries of specialty, institution and geography.
We provide researchers with access to state-of-the-art core facilities that would be beyond the reach of individual laboratories. These shared resources—including genomics platforms, bioinformatics capabilities and specialized technologies—ensure Canadian researchers have the tools they need to compete internationally. By pooling resources and expertise, we maximize efficiency and enable research that would otherwise be impossible.
Training the next generation of genetics researchers is central to our mandate. CGDN supports graduate students, postdoctoral fellows and research associates, providing them with not only financial support but also unique networking opportunities, specialized training programs and exposure to both academic and commercial research environments. Many of our trainees have gone on to leadership positions in academia, biotechnology companies and healthcare institutions.
Understanding genes is only the beginning. CGDN is fundamentally committed to translating genetic discoveries into tools and treatments that make a difference in human health.
Our research has led to breakthrough insights into diseases affecting millions of Canadians. We have identified genetic variations that increase susceptibility to conditions ranging from cancer to infectious diseases, discovered how specific gene mutations influence disease progression, and developed new approaches to diagnosis and risk assessment.
The path from genetic discovery to clinical application requires expertise spanning basic science, clinical research, regulatory affairs and commercialization. CGDN actively facilitates this translation process by:
This integrated approach has enabled numerous CGDN discoveries to move beyond academic publications toward practical application. Our work has contributed to new diagnostic tests, informed treatment decisions and created opportunities for Canadian companies to compete in the global genetics marketplace.
Genetic diseases affect the majority of Canadians. Whether through single-gene disorders, complex conditions with genetic components, or cancer arising from genetic mutations, approximately 60% of all Canadians will experience a genetic disease during their lifetime.
CGDN's research addresses this enormous health burden by building the knowledge base and practical tools needed for prevention, early detection and effective treatment. Our investigators study a broad spectrum of genetic conditions, from rare inherited disorders to common complex diseases, always with the goal of translating understanding into action.
As genetic technologies continue to advance rapidly, CGDN ensures that Canada remains at the forefront of this revolution in medicine. We are building the research capacity, training the personnel and forging the partnerships that will enable Canadians to benefit from the promise of genetics for generations to come.